Our commitment

Pfizer is committed to working toward equitable access to its oral COVID-19 treatment, aiming to deliver safe and effective oral therapeutics as soon as possible and at an affordable price.

To help ensure access, as of November 2022, we have:

- Initiated bilateral outreach to over 100 countries, and have now entered into agreements with many countries around the world.
- To support equitable access globally, we are deploying a pricing structure with three tiers: i) high income ii) upper middle income and iii) lower-middle income and low-income. Low- and lower-middle income countries will pay a not-for-profit price.
- Entered into a voluntary license agreement with the Medicines Patent Pool (MPP) to share intellectual property related to our oral COVID-19 treatment to enable qualified generic medicine manufacturers to produce and distribute generic versions of the treatment. This is one of the largest voluntary license agreements in the world.

The voluntary license is intended to help improve access to COVID-19 treatments for 95 low- and middle-income countries, accounting for 53% of the world’s population.

38 sublicensees signed with MPP

(as of 18 July 2022)

Partnering to advance access

Collaborating with the WHO. Pfizer is closely collaborating with the WHO and its partners in the Therapeutics pillar of the Access to COVID-19 Tools Accelerator (ACT-A), as well as other global health leaders, to enable supply of its oral COVID-19 treatment to more low- and lower-middle-income countries.

UNICEF Supply Agreement. Pfizer signed a supply agreement with UNICEF for up to 4 million treatment courses of its oral COVID-19 treatment for distribution to 137 low- and middle-income countries in 2022 and is in discussions on expanding this agreement.

Global Fund. Pfizer will supply the Global Fund with up to 6 million treatment courses of its oral COVID-19 treatment for supply to 132 Global Fund-eligible low- and middle-income countries in all regions of the world beginning in 2022, subject to local regulatory authorization or approval.

With the MPP, UNICEF and Global Fund agreements, every low and middle income country in the world, except China, now has the potential to access the oral treatment or a generic version through one or more of these pathways.

COVID Treatment Quick Start Consortium

Pfizer has joined the COVID Treatment Quick Start Consortium, a joint initiative implemented with Duke University, the Clinton Health Access Initiative (CHAI), COVID Collaborative andAmericares, with support from Pfizer, Open Society Foundations, and the Conrad N. Hilton Foundation. Pfizer will provide courses of our treatment, as well as financial support, to support the Consortium’s efforts to accelerate COVID-19 testing and improve access to treatments in under-resourced parts of the world.

This information is intended to support policy discussions with policy stakeholders.

1. U.S. FDA Emergency Use Authorization Statement: PAXLOVID has not been approved but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 years of age and older weighing at least 40 kg, with positive results of direct SARS CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.
An Accord for a Healthier World

Pfizer announced Accord for a Healthier World to support access for its oral COVID-19 treatment, in addition to 22 other Pfizer medicines and vaccines, on a not-for-profit-basis to 45 lower-income countries.

Pfizer will also collaborate with governments and global health organizations to help remove barriers to access like diagnostics, training, storage and more to get its oral COVID-19 treatment and other medicines to patients who need them in these countries.

Manufacturing Process and Lead Time

We are constantly looking to improve our processes, shorten timelines. Through this work, we have developed an approach to enable short- and long-term supply to support global needs and will continue to adjust our production to align with a change in demand.

Supply Chain

The primary production site making the drug product is based in Freiburg, Germany where we have extensive technical knowledge and specialized high-volume machines.

Ringaskiddy in Ireland is a primary site for active pharmaceutical ingredient (API) manufacturing. Ascoli (Italy) and Newbridge (Ireland) are also being leveraged for drug product manufacturing and co-packaging with ritonavir.

In June 2022, we announced that our Kalamazoo site in the U.S. will begin making API and registered starting materials (RSMs) for the manufacture of nirmatrelvir.

We are applying our deep heritage in developing oral treatments and the success from developing and scaling of our manufacturing process for the Pfizer-BioNTech COVID-19 vaccine to respond to this global pandemic.

Policy Considerations and Recommendations

Enable Innovation. Manufacturers are engaged in unprecedented collaboration to support R&D and production, thanks in large part to intellectual property (IP) protections and other pro-innovation policies. IP protections are essential to speed up R&D, and facilitate sharing of technology and information to scale up manufacturing. Weakening IP for therapeutics would therefore negatively impact R&D needed to tackle pandemics and undermine at-risk investment in production, all without helping improve patient access.

Invest in Resilient Health Systems. Successful development and production of our oral COVID-19 treatment is dependent on a complex supply chain involving more than 60 materials from 20 supply points including internal Pfizer sites and partners across 10 countries.

Beyond manufacturing, governments and international health organizations need to ensure that systems are in place to prescribe and supply the therapeutic to eligible patients at first sign of infection or at first awareness of an exposure, without requiring patients to be hospitalized.

Support Open Trade. The manufacturing process depends on a complex global network of suppliers, competing for raw materials and equipment. Trade bottlenecks – including export restrictions, regulatory barriers, tariffs, and customs red tape – add uncertainty, cost and delay to both manufacturing and patient access.